Abstract: The present invention relates to the field of antibody fragments, which specifically binds an epitope of human and/or murine FAP and which may be linked to an entity such as a moiety. The antibody fragment and the compound formed may be used for therapy or diagnostic purposes.

Abstract: The present invention relates to the field of antibody fragments, which specifically binds an epitope of human folate receptor alpha (FOLR1) and which may be linked to an entity such as a moiety. The antibody fragment and the compound formed may be used for therapy or diagnostic purposes.

Abstract: The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or a functional fragment thereof, wherein said VHH or a functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for detection, imaging, prognosis and diagnosis of cancer as well as for predicting patient response(s) to therapeutics.

Abstract: Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (VHH), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the VHH, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a ?-emitter and ?-emitter.

Abstract: Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (VHH), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the VHH, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a ?-emitter and ?-emitter.

Abstract: The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or a functional fragment thereof, wherein said VHH or a functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for detection, imaging, prognosis and diagnosis of cancer as well as for predicting patient response(s) to therapeutics.

Abstract: Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (VHH), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the VHH, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a ?-emitter and ?-emitter.

Abstract: The disclosure relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

Abstract: The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or a functional fragment thereof, wherein said VHH or a functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for detection, imaging, prognosis and diagnosis of cancer as well as for predicting patient response(s) to therapeutics.

Abstract: The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or functional fragments thereof, wherein said VHH or functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor or cancer cell, e.g., HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for the prevention and/or treatment of cancer.

Abstract: The present invention relates to nanobodies specifically directed against VCAM-1 and to their use in medical imaging and in diagnostic, prognostic and treatment methods.

Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.

Abstract: The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (MMR) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics. Also, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are useful at different stages of cardiovascular diseases, including post-infarction cardiovascular events. Further, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are particularly useful for the in vivo targeting and/or imaging of vulnerable atherosclerotic plaques.

Abstract: The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.

Abstract: The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or functional fragments thereof, wherein said VHH or functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor or cancer cell, e.g., HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for the prevention and/or treatment of cancer.

Abstract: The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (MMR) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics. Also, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are useful at different stages of cardiovascular diseases, including post-infarction cardiovascular events. Further, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are particularly useful for the in vivo targeting and/or imaging of vulnerable atherosclerotic plaques.

Abstract: The disclosure relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

Abstract: The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

Abstract: The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.

Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.